Treats seizures associated with Lennox-Gastaut Syndrome. ANDA 214817, held by Msn. Rufinamide.
As of Nov 14, 2026, ANDA 214817 (Rufinamide), held by Msn, was first approved by FDA on Apr 15, 2025, with 0 approved supplements and 0 published complete response letters.
Rufinamide oral suspension is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 15, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Rufinamide40MG/ML · suspension;oral | Rufinamide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
